Give me Answer from Adoms and victor and hartisons of medicine on Alzh

Give me Answer from Adoms and victor and hartisons of medicine on Alzheimers disease Diagnosis

Reading File

Finding Sources

Searching PubMed

"Alzheimer Disease"[MeSH Terms] AND diagnosis

Searching the Web

2024 Alzheimer's Association diagnostic criteria Alzheimer's disease blood biomarkers diagnosis

Finding Sources

Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC11350039/

Finding Sources

Alzheimer disease: Diagnosis

Core concept

Alzheimer disease (AD) is diagnosed clinically as a gradually progressive cognitive syndrome, usually beginning with impaired episodic memory, with corroboration from cognitive testing, functional decline, exclusion of other causes, and, where needed, AD biomarkers.

Both Adams and Victor and Harrison’s emphasize that dementia is not simply memory loss. It is cognitive impairment sufficiently severe to interfere with independent daily function.

1. Establish the cognitive syndrome

A. History

Obtain history from both patient and a reliable informant.

Typical AD has:

Insidious onset over months to years
Slow, continuous progression
Early and disproportionate impairment of recent episodic memory
- Repeats questions or stories
- Misplaces items
- Forgets recent conversations or appointments
- Gets lost in familiar places
Later deficits in other domains:
- Language: word-finding difficulty, reduced naming
- Visuospatial ability: disorientation, difficulty driving or handling finances
- Executive function: impaired planning, judgment, organization
- Praxis: difficulty performing learned tasks
Behavioral or neuropsychiatric symptoms may occur later: apathy, depression, irritability, agitation, psychosis, sleep disturbance.

B. Distinguish subjective cognitive decline, MCI, and dementia

Stage	Cognitive testing	Daily functioning
Subjective cognitive decline	Normal for age/education	Independent
Mild cognitive impairment (MCI)	Objective impairment, often memory-predominant	Essentially independent, perhaps less efficient
Dementia due to AD	Objective impairment in one or more cognitive domains	Decline interferes with independent activities of daily living

Amnestic MCI can be a prodromal stage of AD, but it does not by itself establish AD pathology.

2. Cognitive and functional assessment

Perform bedside assessment and formal neuropsychological testing where diagnosis is uncertain.

Bedside screening instruments

Mini-Mental State Examination (MMSE)
Montreal Cognitive Assessment (MoCA)
Mini-Cog
Clock-drawing test

Assess:

Orientation
Attention and working memory
Immediate and delayed recall
Language and naming
Visuospatial construction
Executive function
Praxis
Insight and judgment

A typical early AD pattern is impaired learning and delayed recall that does not normalize with cueing, indicating defective encoding/storage rather than merely impaired retrieval.

Functional assessment

Ask specifically about:

Managing money and medications
Driving and navigation
Cooking and appliance use
Telephone and communication
Work performance
Basic activities: dressing, bathing, feeding, toileting

Loss of independence supports dementia rather than MCI.

3. Physical, neurologic, and mental-status examination

The neurologic examination may be normal in early AD.

Findings that suggest an alternative or mixed diagnosis include:

Early focal neurologic deficits, stepwise course, or vascular risk factors: vascular cognitive impairment
Early visual hallucinations, fluctuating cognition, REM sleep behavior disorder, or spontaneous parkinsonism: dementia with Lewy bodies
Early marked behavioral disinhibition, apathy, loss of empathy, compulsive behavior, or primary language syndrome: frontotemporal dementia
Gait disorder, urinary incontinence, and ventriculomegaly: normal-pressure hydrocephalus
Rapid progression, myoclonus, cerebellar/extrapyramidal signs: prion disease, autoimmune encephalitis, or other rapidly progressive dementia
Prominent depression: depressive cognitive disorder, though depression can coexist with AD

4. Exclude delirium, depression, drugs, and reversible contributors

Before diagnosing AD, exclude conditions that cause or worsen cognitive impairment.

Important assessment points

Delirium: acute onset, fluctuating course, impaired attention, altered consciousness
Depression and other psychiatric illness
Alcohol and substance use
Sedatives, anticholinergic drugs, opioids, antihistamines, antiepileptics, and polypharmacy
Sleep deprivation and obstructive sleep apnea
Hearing or visual impairment
Recent infection, systemic illness, metabolic disturbance

Baseline laboratory evaluation

Common initial investigations include:

Complete blood count
Electrolytes, calcium, glucose
Renal and liver function tests
Thyroid-stimulating hormone
Vitamin B12 level
Folate where clinically indicated
HIV and syphilis testing when risk factors, atypical features, or local epidemiology support testing

Additional tests should be guided by presentation, for example autoimmune testing, toxicology, inflammatory markers, copper studies, or CSF testing in young-onset, rapidly progressive, or atypical disease.

Harrison’s stresses that potentially reversible conditions, especially depression, normal-pressure hydrocephalus, alcohol dependence, and medication adverse effects, may cause or contribute to cognitive impairment. Mixed disease, especially AD plus vascular brain injury, is common in older adults.

5. Structural brain imaging

Obtain MRI brain when possible, or noncontrast CT if MRI is unavailable or contraindicated.

Purposes

Exclude structural mimics:
- Chronic subdural hematoma
- Tumor
- Hydrocephalus
- Large stroke
Identify vascular injury:
- Infarcts
- White-matter disease
- Microbleeds
Support the pattern of neurodegeneration.

Typical supportive MRI features in AD

Medial temporal lobe and hippocampal atrophy
Entorhinal cortical atrophy
Later, temporoparietal and posterior cortical atrophy
Enlarged temporal horns due to hippocampal volume loss

Imaging supports but does not independently prove AD. Significant strategic infarction or extensive small-vessel disease suggests vascular or mixed dementia.

6. Clinical diagnosis of probable AD dementia

A clinical diagnosis of probable AD dementia is appropriate when there is:

Dementia established by history and objective cognitive assessment.
Insidious onset.
Clear progression over time.
Prominent initial impairment in one of the recognized AD presentations:
- Amnestic presentation, most common
- Language-predominant presentation
- Visuospatial-predominant presentation
- Executive dysfunction-predominant presentation
No stronger alternative explanation, such as substantial cerebrovascular disease, Lewy body dementia, frontotemporal dementia, major depression, medication toxicity, or another medical/neurologic disorder.

Classic AD dementia is most often an amnestic, gradually progressive syndrome.

7. Biomarkers for diagnostic confirmation

Biomarkers are particularly useful when:

The presentation is young-onset, atypical, or diagnostically uncertain
Confirmation is needed before disease-modifying anti-amyloid therapy
A specialist memory clinic is evaluating MCI or mild dementia
Distinguishing AD from frontotemporal dementia, Lewy body disease, or nondegenerative causes will alter management

A. CSF biomarkers

The characteristic AD CSF profile is:

Low Aβ42 or low Aβ42/Aβ40 ratio: cerebral amyloid deposition
Raised phosphorylated tau: AD-type tau pathology
Raised total tau: neuronal injury, less specific

B. PET imaging

Amyloid PET: demonstrates cerebral amyloid deposition
Tau PET: demonstrates tau pathology and can help stage disease
FDG-PET: supportive pattern of temporoparietal and posterior cingulate hypometabolism in typical AD

C. Blood-based biomarkers

Plasma biomarkers, particularly p-tau217 and certain p-tau/Aβ ratio assays, are increasingly used in specialist settings. Assay quality, intended-use population, and local availability matter.

The 2024 Alzheimer’s Association criteria allow diagnosis of biologically defined AD using validated “Core 1” biomarkers, including amyloid PET, specified CSF ratios, or sufficiently accurate plasma assays. However, biomarkers should support rather than replace a full clinical evaluation. The criteria currently recommend clinical biomarker use mainly for symptomatic people, not routine testing of cognitively unimpaired individuals, as summarized in the 2024 diagnostic criteria.

8. Diagnostic approach in practice

Confirm that decline is real and progressive using informant history.
Determine whether it is subjective decline, MCI, or dementia based on functional impact.
Perform cognitive screening and neurologic/mental-status examination.
Screen for delirium, depression, sleep problems, alcohol/drug exposure, and medication effects.
Order baseline laboratory tests and MRI/CT.
Consider neuropsychological testing if subtle, early, atypical, medicolegal, or occupationally important.
Use CSF, amyloid PET, tau PET, or validated plasma biomarkers in specialist evaluation when confirmation will affect counseling or treatment.
Diagnose probable AD, possible AD/mixed dementia, or another dementia syndrome based on the complete pattern.

Key exam answer

Diagnosis of Alzheimer disease is primarily clinical. It requires evidence of a gradually progressive cognitive decline, usually beginning with episodic memory impairment, confirmed on objective cognitive testing and causing loss of functional independence in dementia. Diagnosis also requires exclusion of delirium, depression, drug effects, metabolic/endocrine disorders, structural brain lesions, vascular cognitive impairment, Lewy body dementia, and frontotemporal dementia. MRI or CT excludes structural and vascular causes and may show medial temporal/hippocampal atrophy. CSF Aβ/tau assays, amyloid PET, tau PET, FDG-PET, and validated plasma biomarkers provide biological support or confirmation, especially in early, atypical, or treatment-eligible cases.

This synthesis follows the dementia diagnostic approach in Adams and Victor’s Principles of Neurology, 12th ed., chapter “The Neurology of Dementia”, and Harrison’s Principles of Internal Medicine, 22nd ed., chapter 31 “Dementia.”

Give a tabulated form diffrance between LATE, PART, LBD, FTLD

Reading File

Finding Sources

Searching PubMed

LATE PART Lewy body frontotemporal lobar degeneration

Searching the Web

LATE PART Lewy body dementia FTLD pathology clinical features comparison consensus

Feature	LATE	PART	LBD / DLB	FTLD
Full form	Limbic-predominant age-related TDP-43 encephalopathy	Primary age-related tauopathy	Lewy body disease. Clinical dementia syndrome is dementia with Lewy bodies (DLB)	Frontotemporal lobar degeneration
Main abnormal protein	Mislocalized, phosphorylated TDP-43	Tau neurofibrillary tangles, usually 3R/4R tau	Aggregated alpha-synuclein in Lewy bodies and neurites	Most commonly TDP-43 or tau; less often FUS
Key pathology distribution	Limbic structures: amygdala, hippocampus, entorhinal cortex, often with hippocampal sclerosis	Medial temporal lobe: entorhinal cortex, hippocampus, adjacent temporal structures	Brainstem, limbic system, and neocortex. Loss of nigral neurons may occur	Predominantly frontal and anterior temporal cortices
Typical age	Very old age, especially over 80 years	Older adults, increases with age	Usually older adults, often about 60-85 years	Often younger onset than AD or LATE, commonly 45-65 years
Usual clinical syndrome	Slowly progressive amnestic syndrome that mimics Alzheimer disease	Usually mild or absent cognitive symptoms; can cause subtle memory impairment. Severe dementia is uncommon if PART is isolated	Dementia with early deficits in attention, executive and visuospatial function; memory may be less prominent initially	Early behavior/personality change or progressive language disorder; episodic memory often relatively preserved early
Hallmark clinical clues	Marked episodic memory impairment in the oldest-old; may be mistaken for AD	Mild memory impairment with aging, often found incidentally at autopsy	Fluctuating cognition, recurrent well-formed visual hallucinations, REM sleep behavior disorder, spontaneous parkinsonism	Disinhibition, apathy, loss of empathy, compulsive behavior, hyperorality, or primary progressive aphasia
Course	Usually indolent, but decline is faster when AD pathology coexists	Generally slow and limited	Progressive cognitive and motor decline; marked sensitivity to antipsychotics can occur	Progressive decline with increasing behavioral, language, and executive impairment
Relationship to Alzheimer disease	Often coexists with AD neuropathologic change; may explain an AD-like amnestic dementia with little amyloid/tau evidence of AD	Distinguished from AD by absence or minimal beta-amyloid plaques despite tau tangles	AD amyloid and tau co-pathology is common and may worsen the course	Can clinically resemble psychiatric disease or AD, but pathology and regional atrophy differ
MRI tendency	Medial temporal/hippocampal atrophy, sometimes severe and asymmetric	Mild medial temporal atrophy may occur	Relative medial temporal preservation compared with AD; functional imaging may show occipital hypometabolism	Frontal and/or anterior temporal atrophy, often asymmetric
Biomarker status	No validated disease-specific clinical biomarker currently	No definitive standalone clinical biomarker; amyloid biomarkers are negative or minimal	Dopamine transporter imaging may show reduced striatal uptake; MIBG cardiac imaging and polysomnography for REM sleep behavior disorder can support diagnosis	Neurofilament light may be raised but is nonspecific; genetics and imaging may help. No single diagnostic fluid biomarker for all FTLD forms
Definitive diagnosis	Neuropathology at autopsy	Neuropathology at autopsy	Lewy body pathology at autopsy, though DLB can be diagnosed clinically using consensus criteria	Neuropathologic classification at autopsy; clinical FTD syndromes can be diagnosed during life
Important distinction	TDP-43 pathology in the oldest-old, chiefly limbic, with AD-like amnesia	Tauopathy of aging with little or no amyloid	Synucleinopathy characterized by cognitive fluctuation, hallucinations, REM sleep behavior disorder, and parkinsonism	Pathologic umbrella term underlying behavioral-variant FTD and language-led syndromes

One-line differentiation for exams

LATE: TDP-43 limbic proteinopathy in very old people, producing an Alzheimer-like amnestic dementia.
PART: medial temporal tau tangles with absent/minimal amyloid plaques, generally producing mild age-related cognitive impairment rather than severe dementia.
LBD/DLB: alpha-synuclein disease with fluctuating cognition, visual hallucinations, REM sleep behavior disorder, and parkinsonism.
FTLD: frontal/anterior temporal degeneration due mainly to TDP-43 or tau, presenting with early behavior or language change rather than early amnesia.

Important caution

These diseases frequently coexist, particularly in older people. A person with LATE or LBD may also have Alzheimer pathology or vascular brain injury, making the clinical phenotype mixed. Harrison’s notes that mixed pathology is common in late-life dementia. The clinical and epidemiologic features of LATE differ from FTLD-TDP despite both involving TDP-43, as described in the LATE consensus report. For DLB, the core clinical pattern includes fluctuation, visual hallucinations, and parkinsonism, summarized in DLB diagnostic criteria.

.what is Braak staging of Alzheimer

Reading File

Finding Sources

Searching PubMed

Alzheimer Braak staging neurofibrillary tangles

Searching the Web

Braak staging Alzheimer disease neurofibrillary tangle stages transentorhinal limbic neocortical

Braak staging in Alzheimer disease

Braak staging is a neuropathologic staging system for the anatomical spread of tau neurofibrillary tangles (NFTs) in Alzheimer disease.

It has 6 stages, grouped into 3 phases:

Braak stage	Main sites of tau tangles	Phase	Usual clinical relevance
I	Transentorhinal cortex	Transentorhinal	Usually asymptomatic
II	Entorhinal cortex and adjacent transentorhinal areas	Transentorhinal	Usually asymptomatic or subtle memory symptoms
III	Hippocampus, especially CA1, and other limbic regions	Limbic	Mild cognitive impairment may appear
IV	Further limbic involvement, including temporal association cortex	Limbic	Clear episodic-memory impairment, often prodromal AD
V	Widespread association neocortex: frontal, parietal, temporal cortices	Neocortical/isocortical	Established Alzheimer dementia
VI	Primary sensory and motor cortices, with extensive neocortical involvement	Neocortical/isocortical	Advanced dementia

Easy mnemonic

T - L - N

I-II: Transentorhinal
III-IV: Limbic
V-VI: Neocortical

Or:

Entorhinal → Hippocampus/Limbic → Neocortex

Important points

Braak staging describes tau tangle distribution, not amyloid plaque burden.
It is traditionally determined at autopsy, although tau-PET can provide supportive in-vivo information.
Higher Braak stage generally correlates with greater cognitive impairment, but pathology and symptoms do not always match perfectly.
Braak I-IV can occur in aging and in PART, especially when amyloid plaques are absent or scant.
In typical Alzheimer disease, advanced tau spread, usually Braak V-VI, occurs with substantial amyloid pathology.

Harrison’s describes the progression as early medial-temporal involvement followed by temporoparietal, cingulate, dorsolateral prefrontal, and finally primary sensory and motor cortices. This corresponds to the standard Braak neurofibrillary-tangle scheme.

This is a shared conversation. Sign in to Orris to start your own chat.